Search for: "Schwarz Pharma, Inc." Results 1 - 20 of 47
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Apr 2010, 8:44 am by Nolan and Auerbach
Schwarz Pharma, Inc. agreed to pay the United States $22 million to resolve False Claims Act allegations relating to the sale of two drugs that had never been FDA-approved as required by law. [read post]
14 Jul 2011, 9:20 pm by Patent Docs
In the original action, Braintree filed a patent infringement suit against Schwarz Pharma in 2003, after the company submitted an ANDA to manufacture a generic version of MiraLAX. [read post]
30 Oct 2009, 3:11 pm
Schwarz Pharma, Inc., -- F.3d --, 2009 WL 3460808 (7th Cir.) [read post]
25 Jan 2009, 2:44 am
Schwarz Pharma, Inc., 2009 WL 151573 (E.D. [read post]
28 Apr 2010, 11:49 pm by Ben Vernia
According to DOJ’s press release: Schwarz Pharma Inc. will pay $22 million to resolve False Claims Act allegations that the company failed to advise the Centers for Medicare and Medicaid Services (CMS) that two unapproved products did not qualify for coverage under federal health care programs, the Justice Department announced today. [read post]
28 May 2012, 3:30 am
Their lawsuit also named Wyeth Inc., Schwarz Pharma and Alaven Pharmaceutical, who make the brand name version of the drug. [read post]
5 Feb 2018, 9:16 am by Rebecca Tushnet
Schwarz Pharma, Inc., 586 F.3d 500, 513 (7th Cir. 2009) (“[A plaintiff] cannot just intone ‘literal falsity’ and by doing so prove a violation of the Lanham Act. [read post]
9 Jan 2009, 3:00 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
11 May 2009, 5:00 am
She served Schwarz Pharma, a citizen of Delaware, on February 17, and Schwarz removed the case to federal court on February 19.Wyeth Pharmaceuticals, Inc., is a citizen of Pennsylvania, the state in which the lawsuit was filed. [read post]
5 Apr 2010, 4:30 am by Mary Giorgi
Reglan, the name-brand version of the drug, was manufactured by Wyeth, Inc. and Schwarz Pharma, Inc. [read post]
3 Aug 2009, 7:29 am
All responding defendants (Actavis, Inc.; Actavis-Elizabeth, L.L.C.; Barr Pharmaceuticals, Inc.; Baxter Healthcare Corp.; Duramed Pharmaceuticals, Inc.; Pliva, Inc.; Pliva USA, Inc.; Schwarz Pharma, Inc.; Teva Pharmaceuticals USA, Inc.; and Wyeth) opposed centralization, as did one Plaintiff from Vermont. [read post]
14 Oct 2007, 8:39 am
  As a result, the exclusive licensee appealing without the patent owner does not subject the defendant to the possibility of duplicative suits.More detail of Schwarz Pharma, Inc. v. [read post]
15 Apr 2010, 11:42 am by FDABlog HPM
Schwarz Pharma, Inc. et al., 586 F.3d 500 (7th Cir. 2009). [read post]